共 50 条
- [41] Efficacy and safety of once weekly selinexor 40 mg versus 60 mg with pomalidomide and dexamethasone in relapsed and/or refractory multiple myelomaFRONTIERS IN ONCOLOGY, 2024, 14White, DarrellSchiller, Gary J.Madan, SumitLentzsch, SuzanneChubar, EvgeniLavi, NoaVan Domelen, Dane R.Bentur, Ohad S.Baljevic, Muhamed
- [42] Tailored treatment to MRD response: A phase I/II study for newly diagnosed multiple myeloma patients using high dose twice-weekly carfilzomib (45 and 56 mg/m2) in combination with lenalidomide and dexamethasoneAMERICAN JOURNAL OF HEMATOLOGY, 2021, 96 (06) : E193 - E196Korde, NehaMastey, DonnaTavitian, ElizabetMailankody, ShamLesokhin, AlexanderHassoun, HaniSmith, Eric L.Lendvai, NikolettaHultcrantz, MalinShah, UrviTan, CarlynLu, SydneyDiamond, BenjaminSalcedo, MeghanWerner, KellyChung, David J.Scordo, MichaelShah, Gunjan L.Lahoud, OscarLandau, HeatherArcila, MariaHo, CalebRoshal, MikhailDogan, AhmetDerkach, AndriyDevlin, Sean M.Giralt, Sergio A.Landgren, Ola
- [43] Once-weekly versus twice-weekly carfilzomib in patients with newly diagnosed multiple myeloma: a pooled analysis of two phase I/II studiesHAEMATOLOGICA, 2019, 104 (08) : 1640 - 1647Bringhen, SaraMina, RobertoPetrucci, Maria TeresaGaidano, GianlucaBallanti, StelvioMusto, PellegrinoOffidani, MassimoSpada, StefanoBenevolo, GiuliaPonticelli, ElenaGalieni, PieroCavo, MicheleDi Toritto, Tommaso CaravitaDi Raimondo, FrancescoMontefusco, VittorioPalumbo, AntonioBoccadoro, MarioLarocca, Alessandra
- [44] MRD Response-Driven Phase I/II Study for Newly Diagnosed Multiple Myeloma Patients Using Higher Doses of Twice-Weekly Carfilzomib (45 and 56 mg/m2) in Combination with Lenalidomide and DexamethasoneBLOOD, 2017, 130Korde, NehaMailankody, ShamSmith, Eric L.Lendvai, NikolettaHassoun, HaniLesokhin, AlexanderHultcrantz, MalinChung, David J.Shah, Gunjan L.Koehne, GuentherLandau, HeatherRoshal, MikhailDogan, AhmetGiralt, Sergio A.Mastey, DonnaEvancha, NicoleDevlin, Sean M.Landgren, Ola
- [45] MRD-Response Driven Phase I/II Study for Newly Diagnosed Multiple Myeloma Patients Using Higher Doses of Twice-Weekly Carfilzomib (45 and 56 mg/m2) in Combination with Lenalidomide and DexamethasoneBLOOD, 2018, 132Korde, NehaMastey, DonnaMailankody, ShamHassoun, HaniLesokhin, Alexander M.Smith, Eric L.Lendvai, NikolettaHultcrantz, MalinTavitian, ElizabetSalcedo, MeghanSams, AllisonDiab, VictoriaChung, David J.Scordo, MichaelLahoud, Oscar B.Landau, Heather J.Arcila, Maria E.Giralt, SergioHo, CalebRoshal, MikhailDevlin, Sean M.Dogan, AhmetLandgren, Ola
- [46] Comparative Efficacy and Safety of Once Versus Twice Weekly Carfilzomib Based Therapies in Relapsed Refractory Multiple Myeloma-a Systematic ReviewBLOOD, 2019, 134Rehman, Saif UrSharif, SaadBatool, Syeda SabeekaBajwa, HamzaFarooqui, Arafat Ali AliAhmed, ZahoorAnjum, AhmadBin Farooq, TalhaMukhtar, SamanaChaudhary, Sibgha GullTariq, Muhammad JunaidSyed, Tariq Iqtidar SadiqAbdullah, Syed MaazFaisal, Muhammad SalmanAnwer, Faiz
- [47] Carfilzomib 56 mg/m2 twice-weekly in combination with dexamethasone and daratumumab (KdD) versus daratumumab in combination with bortezomib and dexamethasone (DVd): a matching-adjusted indirect treatment comparisonLEUKEMIA & LYMPHOMA, 2022, 63 (08) : 1887 - 1896Weisel, KatjaNooka, Ajay K.Terpos, EvangelosSpencer, AndrewGoldschmidt, HartmutDirnberger, FranziskaDeCosta, LucyYusuf, AkeemKumar, Shaji
- [48] Cost-Effectiveness of Once-Weekly Selinexor, Bortezomib, and Dexamethasone (SVd) Versus Twice-Weekly Bortezomib and Dexamethasone (Vd) in Relapsed or Refractory Multiple MyelomaBLOOD, 2020, 136Patel, KishanParker, Terri L.Di, MengyangBar, NoffarHuntington, Scott F.Giri, Smith
- [49] Multiple myeloma: a comparison of two melphalan conditioning regimens (200 mg/m2 versus 140 mg/m2) for autologous stem cell transplantationBONE MARROW TRANSPLANTATION, 2013, 48 : S226 - S227Julve, M.Hassan, S.Matthews, J.Farrell, M.Guy, A.Popat, R.Smith, M.Oakervee, H.Gribben, J.Cavenagh, J.
- [50] Assessing Outcomes in Patients With Multiple Myeloma Postautologous Stem Cell Transplantation: Contrasting the Effects of Melphalan Dosages at 200 mg/m2 versus 140 mg/m2CLINICAL LYMPHOMA MYELOMA & LEUKEMIA, 2024, 24 (09): : 642 - 647Brown, ZacharyScott, CampbellZhang, Li FangSadek, RamsesClarke, AndreaJillella, AnandKeruakous, Amany R.Clemmons, Amber B.